QTTB

Q32 Bio (QTTB)

About Q32 Bio (QTTB)

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Details

Daily high

$3.07

Daily low

$2.85

Price at open

$3.02

52 Week High

$6.37

52 Week Low

$1.34

Market cap

37.5M

Dividend yield

0.00%

Volume

197,769

Avg. volume

9.5M

P/E ratio

-.88

Q32 Bio News